Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy

Table 2 Ongoing clinical trials of neoadjuvant therapy

Treatment strategy	Study number (name)	Phase	Treatment
Anti-PD-1 + chemotherapy	NCT03838159 (NADIM II)	Phase 2 randomised	3 cycles of carboplatin + paclitaxel +/- nivolumab → surgery → 6 mo of adjuvant nivolumab (experimental arm)
	NCT04728724	Phase 2	Grupo A: sintilimab 2-4 cycles → surgery; Group B: sintilimab + chemotherapy (carboplatin + pemetrexed/gemcitabine/paclitaxel) 2-4 cycles → surgery
	NCT04326153	Phase 2	2 cycles of sintilimab + carboplatin + nab-paclitaxel → surgery → 8 cycles of sintilimab
	NCT04379739	Phase 2	2-4 cycles of camrelizumab + apatinib or camrelizumab + chemotherapy (carboplatin + pemetrexed/ gemcitabine) → surgery
	NCT04061590	Phase 2	2 cycles of pembrolizumab + chemotherapy (cisplatin + pemetrexed) → surgery
	NCT04638582	Phase 2	3 cycles of pembrolizumab +/- chemotherapy (carboplatin + pemetrexed/paclitaxel) → surgery
	NCT04025879	Phase 3	chemotherapy +/- nivolumab → surgery → adjuvant nivolumab (experimental arm)
	NCT02998528 (CheckMate 816)	Phase 3	3 cycles of chemotherapy (platinum doublet) + nivolumab → surgery +/- adjuvant chemotherapy (one experimental arm)
Anti-PD-L1 + chemotherapy	NCT04646837	Phase 2	2 cycles of chemotherapy (platinum-based + nab-paclitaxel) + durvalumab → surgery → durvalumab 1 yr
Anti-PD-L1 + anti-CTLA-4	NCT02998528 (CheckMate 816)	Phase 3	3 cycles of nivolumab + 1 cycle of ipilimumab → surgery +/- adjuvant chemotherapy (one experimental arm)
Anti-PD-1	NCT03197467 (NEOMUN)	Phase 2	2 cycles of pembrolizumab → surgery
Anti-PD-1 + anti-LAG3	NCT04205552 (NEOpredict)	Phase 2	2 cycles of nivolumab +/- relatlimab → surgery
Anti-PD-L1 + radiotherapy	NCT04245514	Phase 2	3 cycles of chemotherapy → 1 cycle durvalumab + radiotherapy → surgery → durvalumab 1 yr
	NCT03237377	Phase 2	2 cycles of durvalumab +/- tremelimumab (antiCTLA-4) + radiotherapy → surgery → adjuvant chemotherapy
	NCT03871153	Phase 2	Carboplatin + paclitaxel + radiotherapy + durvalumab → surgery → durvalumab 1 yr